Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rajeev Shah departed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- ceased serving
- Role
- Member of the Board of Directors
Exact text from the filing
each of John Kollins, Elisabeth Sandoval Little, Heath Lukatch, Michael Riebe, Mutya Harsch, Rajeev Shah, Thomas B. King and Tom Soloway ceased serving as members of the Company’s board of directors at the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Akihisa Mori was appointed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- became
- Role
- Member of the Board of Directors
Exact text from the filing
Ryoichi Nagata, Shuichi Kanazashi, Shunji Haruta and Akihisa Mori became the members of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tom O'Neil departed as Chief Financial Officer at Satsuma Pharmaceuticals, Inc..
- Action
- ceased serving
- Role
- Chief Financial Officer
Exact text from the filing
Tom O'Neil ceased serving as Chief Financial Officer of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tom Soloway departed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- ceased serving
- Role
- Member of the Board of Directors
Exact text from the filing
each of John Kollins, Elisabeth Sandoval Little, Heath Lukatch, Michael Riebe, Mutya Harsch, Rajeev Shah, Thomas B. King and Tom Soloway ceased serving as members of the Company’s board of directors at the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ryoichi Nagata was appointed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- became
- Role
- Member of the Board of Directors
Exact text from the filing
Ryoichi Nagata, Shuichi Kanazashi, Shunji Haruta and Akihisa Mori became the members of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Kollins departed as President and Chief Executive Officer at Satsuma Pharmaceuticals, Inc..
- Action
- ceased serving
- Role
- President and Chief Executive Officer
Exact text from the filing
John Kollins ceased serving as President and Chief Executive Officer of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Shuichi Kanazashi was appointed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- became
- Role
- Member of the Board of Directors
Exact text from the filing
Ryoichi Nagata, Shuichi Kanazashi, Shunji Haruta and Akihisa Mori became the members of the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Kollins departed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- ceased serving
- Role
- Member of the Board of Directors
Exact text from the filing
each of John Kollins, Elisabeth Sandoval Little, Heath Lukatch, Michael Riebe, Mutya Harsch, Rajeev Shah, Thomas B. King and Tom Soloway ceased serving as members of the Company’s board of directors at the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Riebe departed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- ceased serving
- Role
- Member of the Board of Directors
Exact text from the filing
each of John Kollins, Elisabeth Sandoval Little, Heath Lukatch, Michael Riebe, Mutya Harsch, Rajeev Shah, Thomas B. King and Tom Soloway ceased serving as members of the Company’s board of directors at the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Elisabeth Sandoval Little departed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- ceased serving
- Role
- Member of the Board of Directors
Exact text from the filing
each of John Kollins, Elisabeth Sandoval Little, Heath Lukatch, Michael Riebe, Mutya Harsch, Rajeev Shah, Thomas B. King and Tom Soloway ceased serving as members of the Company’s board of directors at the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Shinji Nitanda was appointed as Secretary at Satsuma Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Secretary
Exact text from the filing
Shinji Nitanda – Secretary
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Heath Lukatch departed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- ceased serving
- Role
- Member of the Board of Directors
Exact text from the filing
each of John Kollins, Elisabeth Sandoval Little, Heath Lukatch, Michael Riebe, Mutya Harsch, Rajeev Shah, Thomas B. King and Tom Soloway ceased serving as members of the Company’s board of directors at the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Thomas B. King departed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- ceased serving
- Role
- Member of the Board of Directors
Exact text from the filing
each of John Kollins, Elisabeth Sandoval Little, Heath Lukatch, Michael Riebe, Mutya Harsch, Rajeev Shah, Thomas B. King and Tom Soloway ceased serving as members of the Company’s board of directors at the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mutya Harsch departed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- ceased serving
- Role
- Member of the Board of Directors
Exact text from the filing
each of John Kollins, Elisabeth Sandoval Little, Heath Lukatch, Michael Riebe, Mutya Harsch, Rajeev Shah, Thomas B. King and Tom Soloway ceased serving as members of the Company’s board of directors at the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ryoichi Nagata was appointed as President at Satsuma Pharmaceuticals, Inc..
- Action
- appointed
- Role
- President
Exact text from the filing
Ryoichi Nagata – President
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Shunji Haruta was appointed as Member of the Board of Directors at Satsuma Pharmaceuticals, Inc..
- Action
- became
- Role
- Member of the Board of Directors
Exact text from the filing
Ryoichi Nagata, Shuichi Kanazashi, Shunji Haruta and Akihisa Mori became the members of the Company’s board of directors
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Satsuma Pharmaceuticals, Inc.: The Company's Amended and Restated Certificate of Incorporation was amended and restated in its entirety as the Fifth Amended and Restated Certificate of Incorporation.
- Change
- charter amendment
Exact text from the filing
the Company’s Amended and Restated Certificate of Incorporation was amended and restated in its entirety as set forth in Exhibits to the Merger Agreement (the “Fifth Amended and Restated Certificate of Incorporation”)
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Satsuma Pharmaceuticals, Inc.: The Company's Amended and Restated Bylaws were amended and restated to read in their entirety as the bylaws of Merger Sub immediately prior to the Effective Time.
- Change
- bylaw amendment
Exact text from the filing
the Company’s Amended and Restated Bylaws were amended and restated to read in their entirety as the bylaws of Merger Sub immediately prior to the Effective Time
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Satsuma Pharmaceuticals, Inc. underwent a change of control involving Shin Nippon Biomedical Laboratories, Ltd. for $0.91 per Share and one non-transferable contractual contingent value right (a "CVR") per Share (closed 2023-06-08).
- Action
- change of control
- Counterparty
- Shin Nippon Biomedical Laboratories, Ltd.
- Consideration
- $0.91 per Share and one non-transferable contractual contingent value right (a "CVR") per Share
- Closing
- 2023-06-08
Exact text from the filing
a tender offer (the “Offer”) to acquire all of the issued and outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Shares”) in exchange for (i) $0.91 per Share, net to the seller in cash, without interest thereon and less any applicable withholding taxes and (ii) one non-transferable contractual contingent value right (a “CVR”)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Satsuma Pharmaceuticals, Inc. terminated 2019 Incentive Award Plan with Satsuma Pharmaceuticals, Inc. valued at Terminated upon Merger consummation (effective 2023-06-08).
- Action
- termination
- Agreement
- equity purchase
- Counterparty
- Satsuma Pharmaceuticals, Inc.
- Value
- Terminated upon Merger consummation
- Effective
- 2023-06-08
Exact text from the filing
the Company terminated the Company’s 2016 Equity Incentive Plan, 2019 Incentive Award Plan and 2019 Employee Stock Purchase Plan.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Satsuma Pharmaceuticals, Inc. terminated 2016 Equity Incentive Plan with Satsuma Pharmaceuticals, Inc. valued at Terminated upon Merger consummation (effective 2023-06-08).
- Action
- termination
- Agreement
- equity purchase
- Counterparty
- Satsuma Pharmaceuticals, Inc.
- Value
- Terminated upon Merger consummation
- Effective
- 2023-06-08
Exact text from the filing
the Company terminated the Company’s 2016 Equity Incentive Plan, 2019 Incentive Award Plan and 2019 Employee Stock Purchase Plan.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Satsuma Pharmaceuticals, Inc. terminated 2019 Employee Stock Purchase Plan with Satsuma Pharmaceuticals, Inc. valued at Terminated upon Merger consummation (effective 2023-06-08).
- Action
- termination
- Agreement
- equity purchase
- Counterparty
- Satsuma Pharmaceuticals, Inc.
- Value
- Terminated upon Merger consummation
- Effective
- 2023-06-08
Exact text from the filing
the Company terminated the Company’s 2016 Equity Incentive Plan, 2019 Incentive Award Plan and 2019 Employee Stock Purchase Plan.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Satsuma Pharmaceuticals, Inc. terminated Sales Agreement with Virtu Americas LLC valued at Termination of at-the-market offering facility (effective 2023-06-06).
- Action
- termination
- Agreement
- equity purchase
- Counterparty
- Virtu Americas LLC
- Value
- Termination of at-the-market offering facility
- Effective
- 2023-06-06
Exact text from the filing
As previously disclosed, on November 3, 2022, the Company entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with Virtu Americas LLC (“Virtu”) with respect to an “at-the-market” offering program under which the Company could offer and sell, from time to time at the Company’s sole discretion, shares of its common stock, par value $0.0001 per share, through Virtu as its sales agent.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.